AI Health Platform Lucis Raises $20M Series A

Jan de Vries · 2026-05-26

### A New Era for Preventive Health You've probably heard it before: prevention is better than cure. But what if you could actually see your health risks before they become problems? That's exactly what Lucis is doing, and investors are taking notice. Lucis, a Paris-based preventive health platform, just raised $20 million (€17.1 million) in Series A funding. The round was led by Singular, with participation from General Catalyst, Y Combinator, and several prominent angel investors. This follows their $8.5 million (€7.2 million) Seed round in December 2025, bringing total funding to $28 million (€24 million). ### How Lucis Works Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis combines blood biomarker analysis with AI to give people a comprehensive view of their health. Here's what sets them apart: - Analyzes over 110 blood biomarkers across key systems - Covers metabolic health, hormones, cardiovascular risk, inflammation, and nutrient levels - Integrates results into an AI-driven health companion app - Uses longitudinal data and medical context for personalized advice ### Real Results, Not Just Hype The early data is impressive. Among users who completed a six-month follow-up: - 75% improved at least three biomarkers without medication - More than 80% opted to retest, showing sustained engagement - 99.9% had at least one biomarker outside the optimal range during initial testing (often without knowing it) "We've seen the devastating impact of late-stage diagnosis first-hand," said Maxime Berthelot, co-founder and CEO. "The science is already there; what's missing is a system designed to act before symptoms appear." ### Rapid Growth and Expansion Since launching in 2025, Lucis has grown to over 10,000 users across France, the UK, Ireland, and Portugal. They've conducted more than one million biomarker tests and built a community of thousands. The company has also formed partnerships with major laboratory groups like Eurofins and Randox. Currently, Lucis has a team of 20 people across engineering, clinical, growth, and operations. They also maintain a medical board and a network of over 10 physicians providing clinical oversight. ### What's Next for Lucis With the fresh funding, the company plans to: - Expand into Spain, Germany, and Italy by the end of 2026 - Continue developing their AI-driven health companion app - Invest in personalization, longitudinal monitoring, and clinical safety Jeremy Uzan, co-founder and GP at Singular, said, "Europe's preventive health category will be won by platforms that unite clinical credibility with AI at scale. Lucis has moved with remarkable velocity, reaching 10,000 users in under a year." ### The Bigger Picture What makes Lucis interesting isn't just the technology - it's the shift in mindset. They're making prevention the default, not a privilege. By catching health risks early, they're potentially saving lives and reducing healthcare costs. For US professionals watching European health tech, Lucis represents a model worth studying. The combination of AI, biomarker analysis, and clinical oversight could reshape how we think about preventive medicine. As Berthelot put it: "Europe deserves a healthcare model that doesn't wait for people to get sick. We are making prevention the default."